Correspondence | Published:

Who is wrong? Responses to Kwo et al.

The American Journal of Gastroenterologyvolume 113pages779780 (2018) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Kwo PY, Shiffman ML, Bernstein DE The Cochrane review conclusion for hepatitis C DAA therapies is wrong. Am J Gastroenterol 2017; online publication 14 Nov 2017. https://doi.org/10.1038/ajg.2017.420.

  2. 2.

    Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017: CD012143. 012110.011002/14651858.CD14012143.pub14651852.

  3. 3.

    Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017: CD012143. 012110.011002/14651858.CD14012143.pub14651853.

  4. 4.

    Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med. 2017;15:134.

  5. 5.

    Ciani O, Buyse M, Drummond M, et al. Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value Health. 2017;20:487–95.

  6. 6.

    Gluud C, Brok J, Gong Y, et al. Hepatology may have problems with putative surrogate outcome measures. J Hepatol. 2007;46:734–42.

  7. 7.

    Koretz RL, Pleguezuelo M, Arvaniti V, et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev. 2013 (1): CD003617. doi: 003610.001002/14651858.CD14003617.pub14651852.

  8. 8.

    Myers RP, Regimbeau C, Thevenot T, et al.Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD000370. DOI: 10.1002/14651858.CD000370.

  9. 9.

    van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. J Am Med Assoc. 2012;308:2584–93.

  10. 10.

    Lens S, Rincon D, Garcia-Retortillo M, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol. 2015;13:1846–53.e1.

  11. 11.

    van der Meer AJ, Wedemeyer H, Feld JJ, et al. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? J Hepatol. 2014;60:191–6.

  12. 12.

    Flemming JA, Kim WR, Brosgart CL, et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;65:804–12.

  13. 13.

    Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus–infected patients awaiting liver transplantation. Liver Transplant. 2002;8:350–5.

  14. 14.

    Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65:524–31.

  15. 15.

    Dusheiko G. The impact of antiviral therapy for hepatitis C on the quality of life: a perspective. Liver Int. 2017;37:7–12.

  16. 16.

    Koretz RL, Lin KW, Ioannidis JP, Lenzer J. Is widespread screening for hepatitis C justified? BMJ. 2015;350:g7809. doi: https://doi.org/7810.1136/bmj.g7809

  17. 17.

    Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C (Protocol). The Cochrane Library. 2016. 10.1002/14651858.CD012143

  18. 18.

    Bruix J, Poynard T, Colombo M, et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011;140:1990–9.

  19. 19.

    Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004;25:472–92.

  20. 20.

    Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–59.

  21. 21.

    Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–97.

  22. 22.

    Poordad F, Schiff E, Vierling J, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 ALLY-1 study. J Hepatol. 2015;62:S261. (Suppl 2)

Download references

Author information

Affiliations

  1. Granada Hills, Los Angeles, CA, USA

    • Ronald L. Koretz
  2. The Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

    • Janus Christian Jakobsen
    •  & Christian Gluud
  3. Department of Cardiology, Holbaek Hospital, Holbaek, Denmark

    • Janus Christian Jakobsen
  4. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

    • Snezana Djurisic
  5. Department of Gastroenterology, Clinical Hospital Centre Rijeka, Rijeka, Croatia

    • Goran Poropat
    •  & Goran Hauser
  6. Medical Faculty, University of Nis, Nis, Serbia

    • Milica Bjelakovic
  7. Department of Internal Medicine, Medical Faculty, University of Nis, Nis, Serbia

    • Goran Bjelakovic

Authors

  1. Search for Ronald L. Koretz in:

  2. Search for Janus Christian Jakobsen in:

  3. Search for Snezana Djurisic in:

  4. Search for Goran Poropat in:

  5. Search for Goran Hauser in:

  6. Search for Milica Bjelakovic in:

  7. Search for Goran Bjelakovic in:

  8. Search for Christian Gluud in:

Guarantor of the article

Janus Christian Jakobsen.

Specific author contributions

All authors contributed equally to the letter.

Financial support

None.

Potential competing interests

None.

Corresponding author

Correspondence to Janus Christian Jakobsen.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41395-018-0029-4